688177 百奥泰
已收盘 12-26 15:00:01
资讯
新帖
简况
百奥泰(688177.SH)：维拉西塔单抗注射液(BAT5906)上市许可申请获得受理
智通财经 · 12-18
百奥泰(688177.SH)：维拉西塔单抗注射液(BAT5906)上市许可申请获得受理
百奥泰(688177.SH)：Gotenfia®(戈利木单抗注射液)获欧洲药品管理局人用药品委员会积极意见
智通财经 · 12-12
百奥泰(688177.SH)：Gotenfia®(戈利木单抗注射液)获欧洲药品管理局人用药品委员会积极意见
每周股票复盘：百奥泰（688177）将召开2025年第三季度业绩说明会
证券之星 · 11-16
每周股票复盘：百奥泰（688177）将召开2025年第三季度业绩说明会
百奥泰（688177）披露将召开2025年第三季度业绩说明会，11月12日股价上涨0.88%
证券之星 · 11-12
百奥泰（688177）披露将召开2025年第三季度业绩说明会，11月12日股价上涨0.88%
百奥泰公布国际专利申请：“抗Nectin-4抗体药物偶联物治疗肿瘤的方法”
证券之星 · 11-08
百奥泰公布国际专利申请：“抗Nectin-4抗体药物偶联物治疗肿瘤的方法”
每周股票复盘：百奥泰（688177）Q3营收增34.92%，净亏缩窄
证券之星 · 11-02
每周股票复盘：百奥泰（688177）Q3营收增34.92%，净亏缩窄
百奥泰（688177）2025年三季报简析：营收上升亏损收窄，盈利能力上升
证券之星 · 10-30
百奥泰（688177）2025年三季报简析：营收上升亏损收窄，盈利能力上升
图解百奥泰三季报：第三季度单季净利润同比增长23.00%
证券之星 · 10-28
图解百奥泰三季报：第三季度单季净利润同比增长23.00%
百奥泰(688177)9月30日股东户数0.94万户，较上期减少0.89%
证券之星 · 10-28
百奥泰(688177)9月30日股东户数0.94万户，较上期减少0.89%
百奥泰最新公告：收到STADA支付的850万欧元首付款
证券之星 · 10-17
百奥泰最新公告：收到STADA支付的850万欧元首付款
百奥泰宣布扩大与Intas Pharmaceuticals的合作伙伴关系，通过在加拿大的独家商业化和许可协议推进Bat2506这一拟参照Simponi®（戈利木单抗）的生物类似药项目
美股速递 · 10-09
百奥泰宣布扩大与Intas Pharmaceuticals的合作伙伴关系，通过在加拿大的独家商业化和许可协议推进Bat2506这一拟参照Simponi®（戈利木单抗）的生物类似药项目
百奥泰（688177）披露核心技术人员离职公告，9月30日股价下跌0.21%
证券之星 · 09-30
百奥泰（688177）披露核心技术人员离职公告，9月30日股价下跌0.21%
百奥泰公布国际专利申请：“治疗宫颈癌、胸腺肿瘤或激素受体阳性和HER2阴性乳腺癌的方法”
证券之星 · 09-23
百奥泰公布国际专利申请：“治疗宫颈癌、胸腺肿瘤或激素受体阳性和HER2阴性乳腺癌的方法”
股市必读：百奥泰（688177）9月19日披露最新机构调研信息
证券之星 · 09-22
股市必读：百奥泰（688177）9月19日披露最新机构调研信息
百奥泰：9月11日接受机构调研，自然人股东参与
证券之星 · 09-11
百奥泰：9月11日接受机构调研，自然人股东参与
百奥泰最新公告：收到540万美元里程碑付款
证券之星 · 09-11
百奥泰最新公告：收到540万美元里程碑付款
百奥泰(688177.SH)：Qletli®(阿达木单抗注射液)获得英国MHRA上市批准
智通财经 · 09-10
百奥泰(688177.SH)：Qletli®(阿达木单抗注射液)获得英国MHRA上市批准
百奥泰涨8.03%，太平洋四日前给出“买入”评级
证券之星 · 09-01
百奥泰涨8.03%，太平洋四日前给出“买入”评级
每周股票复盘：百奥泰（688177）机构净买入482.16万元
证券之星 · 08-31
每周股票复盘：百奥泰（688177）机构净买入482.16万元
8月29日百奥泰现1笔大宗交易 机构净买入482.16万元
证券之星 · 08-29
8月29日百奥泰现1笔大宗交易 机构净买入482.16万元
加载更多
公司概况
公司名称：
百奥泰生物制药股份有限公司
所属行业：
医药制造业
上市日期：
2020-02-21
主营业务：
百奥泰生物制药股份有限公司的主营业务是创新药和生物类似药的研发。公司的主要产品是创新药、生物类似药。
发行价格：
32.76
{"stockData":{"symbol":"688177","market":"SH","secType":"STK","nameCN":"百奥泰","latestPrice":23.59,"timestamp":1766732401000,"preClose":23.67,"halted":0,"volume":1312778,"delay":0,"changeRate":-0.0034,"floatShares":413999999,"shares":413999999,"eps":-0.8908,"marketStatus":"已收盘","change":-0.08,"latestTime":"12-26 15:00:01","open":23.67,"high":23.78,"low":23.38,"amount":30982400,"amplitude":0.0169,"askPrice":23.59,"askSize":1,"bidPrice":23.55,"bidSize":4,"shortable":0,"etf":0,"ttmEps":-0.8908,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766971800000},"marketStatusCode":5,"adr":0,"adjPreClose":23.67,"symbolType":"stock_kcb","openAndCloseTimeList":[[1766712600000,1766719800000],[1766725200000,1766732400000]],"highLimit":26.04,"lowLimit":21.3,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":414080000,"isCdr":false,"pbRate":20.18,"roa":"--","roe":"--","epsLYR":-1.23,"committee":-0.434343,"marketValue":9768000000,"turnoverRate":0.0032,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2025-12-29。","afterMarket":{"amount":0,"volume":0,"close":23.59,"buyVolume":0,"sellVolume":0,"time":1766734437768,"indexStatus":"已收盘 12-26 15:30:00","preClose":23.67},"floatMarketCap":9768000000},"requestUrl":"/m/hq/s/688177","defaultTab":"news","newsList":[{"id":"2592979087","title":"百奥泰(688177.SH)：维拉西塔单抗注射液(BAT5906)上市许可申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2592979087","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592979087?lang=zh_cn&edition=full","pubTime":"2025-12-18 17:23","pubTimestamp":1766049781,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百奥泰 发布公告，公司于近日收到国家药品监督管理局核准签发的关于公司在研药品维拉西塔单抗注射液药品上市许可申请的《受理通知书》。在体外血管生成模型上，BAT5906能够阻断VEGF与其相应的受体结合，抑制内皮细胞的增殖和新生血管形成。在动物实验中，BAT5906在猴玻璃体中半衰期比结构为Fab片段的雷珠单抗更长，可能会支持临床中更长的注射周期。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383145.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"百奥泰(688177.SH)：维拉西塔单抗注射液(BAT5906)上市许可申请获得受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688177","BK0239"],"gpt_icon":0},{"id":"2590576059","title":"百奥泰(688177.SH)：Gotenfia®(戈利木单抗注射液)获欧洲药品管理局人用药品委员会积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2590576059","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590576059?lang=zh_cn&edition=full","pubTime":"2025-12-12 16:00","pubTimestamp":1765526426,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百奥泰 发布公告，公司于近日收到了欧洲药品管理局的通知，Gotenfia获得EMA人用药品委员会积极意见。CHMP建议欧盟委员会批准Gotenfia上市，用于治疗类风湿关节炎，幼年特发性关节炎，银屑病关节炎，中轴型脊柱关节炎，溃疡性结肠炎。BAT2506是百奥泰根据中国国家药品监督管理局、美国食品药品监督管理局、EMA生物类似药相关指导原则开发的戈利木单抗生物类似药。BAT2506的原研药为美国强生公司的Simponi (欣普尼)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380853.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"百奥泰(688177.SH)：Gotenfia®(戈利木单抗注射液)获欧洲药品管理局人用药品委员会积极意见","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688177"],"gpt_icon":0},{"id":"2583977654","title":"每周股票复盘：百奥泰（688177）将召开2025年第三季度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2583977654","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583977654?lang=zh_cn&edition=full","pubTime":"2025-11-16 04:52","pubTimestamp":1763239930,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，百奥泰报收于26.69元，较上周的26.0元上涨2.65%。本周，百奥泰11月14日盘中最高价报27.1元。本周关注点公司公告汇总：百奥泰将于2025年11月24日召开第三季度业绩说明会。公司公告汇总百奥泰生物制药股份有限公司将于2025年11月24日09:00-10:00通过上证路演中心网络互动方式召开2025年第三季度业绩说明会，介绍公司经营成果及财务状况。说明会结束后可通过上证路演中心查看会议情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600001443.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"gpt_icon":0},{"id":"2582370733","title":"百奥泰（688177）披露将召开2025年第三季度业绩说明会，11月12日股价上涨0.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582370733","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582370733?lang=zh_cn&edition=full","pubTime":"2025-11-12 22:55","pubTimestamp":1762959319,"startTime":"0","endTime":"0","summary":"截至2025年11月12日收盘，百奥泰报收于26.29元，较前一交易日上涨0.88%，最新总市值为108.86亿元。公司近日发布公告称，百奥泰生物制药股份有限公司将于2025年11月24日09:00-10:00通过上证路演中心网络互动方式召开2025年第三季度业绩说明会，介绍公司经营成果及财务状况。投资者可于2025年11月17日至11月21日16:00前通过上证路演中心网站或公司邮箱IR@bio-thera.com提问。说明会结束后可通过上证路演中心查看会议情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200041825.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"gpt_icon":0},{"id":"2581834580","title":"百奥泰公布国际专利申请：“抗Nectin-4抗体药物偶联物治疗肿瘤的方法”","url":"https://stock-news.laohu8.com/highlight/detail?id=2581834580","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581834580?lang=zh_cn&edition=full","pubTime":"2025-11-08 05:37","pubTimestamp":1762551456,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示百奥泰（688177）公布了一项国际专利申请，专利名为“抗Nectin-4抗体药物偶联物治疗肿瘤的方法”，专利申请号为PCT/CN2025/091722，国际公布日为2025年11月6日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来百奥泰已公布的国际专利申请14个，较去年同期增加了7.69%。结合公司2025年中报财务数据，今年上半年公司在研发方面投入了3.49亿元，同比减13.34%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110800003413.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"gpt_icon":0},{"id":"2580405200","title":"每周股票复盘：百奥泰（688177）Q3营收增34.92%，净亏缩窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2580405200","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580405200?lang=zh_cn&edition=full","pubTime":"2025-11-02 10:37","pubTimestamp":1762051028,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，百奥泰报收于27.58元，较上周的26.7元上涨3.3%。本周，百奥泰10月31日盘中最高价报27.84元。百奥泰当前最新总市值114.2亿元，在生物制品板块市值排名26/51，在两市A股市值排名1678/5163。股本股东变化截至2025年9月30日，百奥泰股东户数为9397户，较6月30日减少84户，减幅0.89%。业绩披露要点百奥泰2025年三季报显示，主营收入6.84亿元，同比上升17.57%；归母净利润-2.24亿元，同比上升38.72%；扣非净利润-2.79亿元，同比上升31.12%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200002432.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177"],"gpt_icon":0},{"id":"2579130570","title":"百奥泰（688177）2025年三季报简析：营收上升亏损收窄，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2579130570","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579130570?lang=zh_cn&edition=full","pubTime":"2025-10-30 06:16","pubTimestamp":1761776190,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期百奥泰发布2025年三季报。截至本报告期末，公司营业总收入6.84亿元，同比上升17.57%，归母净利润-2.24亿元，同比上升38.72%。本报告期百奥泰盈利能力上升，毛利率同比增幅11.75%，净利率同比增幅47.88%。），公司上市来已有年报4份，亏损年份8次，如无借壳上市等因素，价投一般不看这类公司。持有百奥泰最多的基金为鹏华安泽混合A，目前规模为0.13亿元，最新净值1.2047，较上一交易日上涨0.07%，近一年上涨2.67%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000005147.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177"],"gpt_icon":0},{"id":"2578930847","title":"图解百奥泰三季报：第三季度单季净利润同比增长23.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578930847","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578930847?lang=zh_cn&edition=full","pubTime":"2025-10-28 18:47","pubTimestamp":1761648443,"startTime":"0","endTime":"0","summary":"证券之星消息，百奥泰2025年三季报显示，公司主营收入6.84亿元，同比上升17.57%；归母净利润-2.24亿元，同比上升38.72%；扣非净利润-2.79亿元，同比上升31.12%；其中2025年第三季度，公司单季度主营收入2.42亿元，同比上升34.92%；单季度归母净利润-9892.58万元，同比上升23.0%；单季度扣非净利润-1.07亿元，同比上升19.93%；负债率78.27%，投资收益39.08万元，财务费用1174.4万元，毛利率78.3%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800035139.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177"],"gpt_icon":0},{"id":"2578936913","title":"百奥泰(688177)9月30日股东户数0.94万户，较上期减少0.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578936913","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578936913?lang=zh_cn&edition=full","pubTime":"2025-10-28 17:23","pubTimestamp":1761643422,"startTime":"0","endTime":"0","summary":"证券之星消息，近日百奥泰披露，截至2025年9月30日公司股东户数为9397.0户，较6月30日减少84.0户，减幅为0.89%。在生物制品行业个股中，百奥泰股东户数低于行业平均水平，截至9月30日，生物制品行业平均股东户数为3.42万户。从股价来看，2025年6月30日至2025年9月30日，百奥泰区间涨幅为15.44%，在此期间股东户数减少84.0户，减幅为0.89%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800031213.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"gpt_icon":0},{"id":"2576080585","title":"百奥泰最新公告：收到STADA支付的850万欧元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2576080585","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576080585?lang=zh_cn&edition=full","pubTime":"2025-10-17 17:01","pubTimestamp":1760691700,"startTime":"0","endTime":"0","summary":"百奥泰(688177.SH)公告称，公司于北京时间2025年8月20日与STADA签署授权许可与商业化协议，将BAT1806（托珠单抗）注射液在多国市场的独占商业化权益有偿许可给STADA，首付款及里程碑款总金额最高至1.36亿欧元。公司于近日收到STADA支付的850万欧元首付款，这将进一步充盈公司的现金储备，为后续管线研发和国际化战略推进提供助力。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101700026407.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["MEURmain","BK0239","FXE","EUO","688177","EURmain"],"gpt_icon":0},{"id":"1103806445","title":"百奥泰宣布扩大与Intas Pharmaceuticals的合作伙伴关系，通过在加拿大的独家商业化和许可协议推进Bat2506这一拟参照Simponi®（戈利木单抗）的生物类似药项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1103806445","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103806445?lang=zh_cn&edition=full","pubTime":"2025-10-09 20:43","pubTimestamp":1760013789,"startTime":"0","endTime":"0","summary":"百奥泰宣布扩大与Intas Pharmaceuticals的合作伙伴关系，双方将通过在加拿大的独家商业化和许可协议，共同推进Bat2506这一拟参照Simponi®（戈利木单抗）的生物类似药项目。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688177","BK0239"],"gpt_icon":0},{"id":"2571343801","title":"百奥泰（688177）披露核心技术人员离职公告，9月30日股价下跌0.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2571343801","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571343801?lang=zh_cn&edition=full","pubTime":"2025-09-30 17:37","pubTimestamp":1759225071,"startTime":"0","endTime":"0","summary":"截至2025年9月30日收盘，百奥泰报收于28.93元，较前一交易日下跌0.21%，最新总市值为119.79亿元。近日，百奥泰生物制药股份有限公司发布公告称，公司核心技术人员YU JIN-CHEN（俞金泉）因个人原因申请不再继续返聘，已办理离职手续，不再担任公司任何职务。俞金泉离职不会对公司核心技术、研发项目、核心竞争力及持续经营能力产生重大不利影响。工作已交接完毕，核心技术人员由5人变更为4人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025093000029277.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"gpt_icon":0},{"id":"2569816753","title":"百奥泰公布国际专利申请：“治疗宫颈癌、胸腺肿瘤或激素受体阳性和HER2阴性乳腺癌的方法”","url":"https://stock-news.laohu8.com/highlight/detail?id=2569816753","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569816753?lang=zh_cn&edition=full","pubTime":"2025-09-23 05:25","pubTimestamp":1758576337,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示百奥泰（688177）公布了一项国际专利申请，专利名为“治疗宫颈癌、胸腺肿瘤或激素受体阳性和HER2阴性乳腺癌的方法”，专利申请号为PCT/CN2025/081754，国际公布日为2025年9月18日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来百奥泰已公布的国际专利申请13个，较去年同期增加了30%。结合公司2025年中报财务数据，今年上半年公司在研发方面投入了3.49亿元，同比减13.34%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092300003437.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"gpt_icon":0},{"id":"2569423220","title":"股市必读：百奥泰（688177）9月19日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2569423220","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569423220?lang=zh_cn&edition=full","pubTime":"2025-09-22 03:35","pubTimestamp":1758483316,"startTime":"0","endTime":"0","summary":"截至2025年9月19日收盘，百奥泰报收于29.7元，下跌1.69%，换手率0.62%，成交量2.55万手，成交额7640.84万元。来自机构调研要点：公司创新药BT5906已完成wMD III期临床并获积极结果，年内将提交上市申请。针对创新药研发进展，公司表示贝塔宁已获批上市，BT5906已完成wMD III期临床并获得积极结果，将在年内提交上市申请；BT4406F已完成视神经脊髓炎关键注册临床研究并取得积极结果，计划于2026年上半年申报上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092200001160.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"gpt_icon":0},{"id":"2566960265","title":"百奥泰：9月11日接受机构调研，自然人股东参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2566960265","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566960265?lang=zh_cn&edition=full","pubTime":"2025-09-11 19:33","pubTimestamp":1757590429,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年9月11日百奥泰发布公告称公司于2025年9月11日接受机构调研，自然人股东参与。若 BT7111 在临床研究中取得成功，公司有望在此基础上进行进一步开发。百奥泰的 BT1308+DC 组合，是基于我们自己 DC 的特点选择在某些肿瘤中进行临床开发的。目前还没有数据支持PD1/VEGF 双抗与 DC 联合优于 PD1 抗体联合 DC。后续如有明确计划，公司将严格按照监管要求及时履行信息披露义务。百奥泰主营业务：药物的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091100033931.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"gpt_icon":0},{"id":"2566196485","title":"百奥泰最新公告：收到540万美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2566196485","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566196485?lang=zh_cn&edition=full","pubTime":"2025-09-11 18:21","pubTimestamp":1757586084,"startTime":"0","endTime":"0","summary":"百奥泰(688177.SH)公告称，此前批露，公司与Intas签署授权许可与商业化协议，将公司的BAT2506（戈利木单抗）注射液在美国市场的独占的产品商业化权益有偿许可给Intas公司于近日收到Intas支付的540.00万美元里程碑付款，按照2025年9月11日中国人民银行公布的美元兑人民币中间价7.1034，共计人民币3,835.84万元。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091100030622.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"gpt_icon":0},{"id":"2566763546","title":"百奥泰(688177.SH)：Qletli®(阿达木单抗注射液)获得英国MHRA上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2566763546","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566763546?lang=zh_cn&edition=full","pubTime":"2025-09-10 16:16","pubTimestamp":1757492184,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百奥泰(688177.SH)发布公告，公司于近日收到了英国药品和健康产品管理局(简称“英国MHRA”)签发的关于Qletli®(BAT1406，阿达木单抗注射液)上市批准通知。BAT1406是百奥泰自主研发的阿达木单抗生物类似药，是由CHO细胞表达的重组全人源单克隆抗体，通过与TNF-α特异性结合并中和其生物学功能，阻断其与细胞表面TNF-α受体的相互作用，从而阻断TNF-α的致炎作用。Qletli®获得英国MHRA上市批准后可在英国进行销售，公司海外销售产品品类得到进一步扩充，将进一步提升公司产品的国际影响力，有望对公司长期经营业绩产生积极影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1343586.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"百奥泰(688177.SH)：Qletli®(阿达木单抗注射液)获得英国MHRA上市批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688177","BK0239"],"gpt_icon":0},{"id":"2564897267","title":"百奥泰涨8.03%，太平洋四日前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2564897267","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564897267?lang=zh_cn&edition=full","pubTime":"2025-09-01 16:22","pubTimestamp":1756714962,"startTime":"0","endTime":"0","summary":"今日百奥泰（688177）涨8.03%，收盘报34.72元。2025年8月28日，太平洋研究员谭紫媚,张懿发布了对百奥泰的研报《百奥泰：核心产品逐步放量，FRαADC关键临床开始入组》，该研报对百奥泰给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为11.22%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为中金公司的刘雅馨、张琎、朱言音。百奥泰（688177）个股概况：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090100021123.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601099","688177"],"gpt_icon":0},{"id":"2563838856","title":"每周股票复盘：百奥泰（688177）机构净买入482.16万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2563838856","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563838856?lang=zh_cn&edition=full","pubTime":"2025-08-31 06:32","pubTimestamp":1756593141,"startTime":"0","endTime":"0","summary":"截至2025年8月29日收盘，百奥泰报收于32.14元，较上周的32.94元下跌2.43%。本周，百奥泰8月25日盘中最高价报33.47元。8月28日盘中最低价报29.65元。百奥泰当前最新总市值133.09亿元，在生物制品板块市值排名24/50，在两市A股市值排名1423/5152。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025083100002157.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"gpt_icon":0},{"id":"2563904514","title":"8月29日百奥泰现1笔大宗交易 机构净买入482.16万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2563904514","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563904514?lang=zh_cn&edition=full","pubTime":"2025-08-29 17:45","pubTimestamp":1756460749,"startTime":"0","endTime":"0","summary":"证券之星消息，8月29日百奥泰发生大宗交易，交易数据如下：大宗交易成交价格31.35元，相对当日收盘价折价2.46%，成交15.38万股，成交金额482.16万元，买方营业部为机构专用，卖方营业部为中信证券股份有限公司北京分公司。近三个月该股共发生1笔大宗交易，合计成交1538.0手，折价成交1笔。截至2025年8月29日收盘，百奥泰报收于32.14元，上涨3.78%，换手率1.15%，成交量4.77万手，成交额1.5亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082900034048.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766824955588,"stockEarnings":[{"period":"1week","weight":0.0111},{"period":"1month","weight":-0.0657},{"period":"3month","weight":-0.1766},{"period":"6month","weight":-0.0534},{"period":"1year","weight":0.1783},{"period":"ytd","weight":0.2172}],"compareEarnings":[{"period":"1week","weight":0.0188},{"period":"1month","weight":0.0257},{"period":"3month","weight":0.0354},{"period":"6month","weight":0.1575},{"period":"1year","weight":0.1664},{"period":"ytd","weight":0.1826}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"百奥泰生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"9397人(较上一季度减少0.89%)","perCapita":"44065股","listingDate":"2020-02-21","address":"广东省广州市海珠区国际生物岛螺旋二路18号","registeredCapital":"41408万元","survey":" 百奥泰生物制药股份有限公司的主营业务是创新药和生物类似药的研发。公司的主要产品是创新药、生物类似药。","listedPrice":32.76},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百奥泰(688177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百奥泰(688177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百奥泰,688177,百奥泰股票,百奥泰股票老虎,百奥泰股票老虎国际,百奥泰行情,百奥泰股票行情,百奥泰股价,百奥泰股市,百奥泰股票价格,百奥泰股票交易,百奥泰股票购买,百奥泰股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百奥泰(688177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百奥泰(688177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}